Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 738 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo (dextrose) Clear all

Conditions: Obesity
Interventions: Soluble Fiber, Placebo; Other
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 18 Years and older
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Chronic Heart Failure With Reduced Systolic Function
Interventions: Dapagliflozin, Dapagliflozin matching placebo; Drug
Lead sponsor: Saint Luke's Health System; Other
Eligibility: 19 Years to 119 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 25
States / cities: Fairhope, Alabama • Los Angeles, California • Jacksonville, Florida + 20 more

Conditions: Coronary Artery Disease
Interventions: Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Alcohol Use Disorder
Interventions: Suvorexant 10 mg, Placebo; Drug · Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Impaired Glucose Tolerance
Interventions: resveratrol, Placebo; Dietary Supplement · Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 50 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Obstructive Sleep Apnea
Interventions: Propranolol Oral Tablet, Placebo Oral Tablet; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 20 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Critically Ill, Respiratory Failure
Interventions: Thiamine; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Kidney Disease
Interventions: Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD; Drug
Lead sponsor: Mineralys Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 44
States / cities: Glendale, Arizona • Phoenix, Arizona • Chula Vista, California + 39 more

Conditions: Type II Diabetes
Interventions: Farxiga, Placebo, Metformin, Insulin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Huntington Park, California + 23 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Saxagliptin, Dapagliflozin, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: NNC 90-1170; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 30 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Diabetes Mellitus, Type 2
Interventions: Carbohydrate placebo, Nutritional ingredient, #1 Nutritional ingredient +Fiber, #2 Nutritional ingredient + Fiber, #3 Nutritional ingredient + Fiber; Other
Lead sponsor: Abbott Nutrition; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Insulin Resistance
Interventions: Last 5 amino acids of GLP-1, placebo saline; Drug
Lead sponsor: Elahi, Dariush, PhD; Individual
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Acute Lung Injury, Sepsis
Interventions: Ascorbic Acid, Placebo: 5% Dextrose in water; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 5
States / cities: Atlanta, Georgia • Lexington, Kentucky • Cleveland, Ohio + 2 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions: Pembrolizumab, Placebo for pembrolizumab, Carboplatin, Paclitaxel, Olaparib, Placebo for olaparib, Bevacizumab, Docetaxel; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 43
States / cities: Birmingham, Alabama • Tucson, Arizona • Burbank, California + 37 more

Conditions: Cannabis Use, Healthy
Interventions: Placebo oral capsule, THC; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 25 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Insulin Resistance
Interventions: Novel dietary fiber, Placebo; Other
Lead sponsor: Cargill; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Insulin Sensitivity
Interventions: Maltodextrin, Synbiotic, Sevelamer; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy
Interventions: PF-02545920, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: New Haven, Connecticut

Conditions: Type2 Diabetes Mellitus
Interventions: BTI320, Placebo; Drug · Other
Lead sponsor: Boston Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Ventura, California • Albuquerque, New Mexico • Mt. Pleasant, South Carolina + 1 more

Conditions: Measuring THC-induced Cognitive Impairment Using a Mobile Application
Interventions: Dronabinol, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 35 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Kidney Disease, Type 2 Diabetes
Interventions: Finerenone (Kerendia, BAY94-8862), Sodium-glucose cotransporter-2 inhibitors (SGLT2i); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 17,847 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions: Canakinumab 150 mg, Placebo to Canakinumab; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 11
States / cities: Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more

Conditions: Septic Shock
Interventions: Hydroxocobalamin, Placebo; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Search by objective public record fields.

Meta-analysis of Soluble Fiber Consumption on Body Weight, Glycemia, and Insulinemia in Overweight and Obese Adults.

Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure

Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery

Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking

Pilot Study of Resveratrol in Older Adults With Impaired Glucose Tolerance

Propranolol for Sleep Apnea Therapy

The Effect of Thiamine vs. Placebo on VO2 in Critical Illness

Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria

Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin

ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study

NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes

Post Prandial Glucose Control Proof-of-Principle

The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body Glucose Metabolism in Man

Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

Reward and Drug Effects on Mood and Brain Response

Effects of Novel Fiber on Glucose Homeostasis in Individuals at Risk for Diabetes

Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)

Evaluation Of Striatal Glucose Metabolism With Positron Emission Tomography Following PF-02545920 In Healthy Subjects

Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes

Developing a Mobile Method to Measure THC-induced Impairment

An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

A Trial of Vitamin B12 in Septic Shock